ClinicalTrials.gov record
6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA
ClinicalTrials.gov ID: NCT00360243
Public ClinicalTrials.gov record NCT00360243. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meet standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.
Study identification
- NCT ID
- NCT00360243
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,385 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 50 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2006
- Primary completion
- Mar 31, 2008
- Completion
- Mar 31, 2008
- Last update posted
- Jun 26, 2016
2006 – 2008
United States locations
- U.S. sites
- 81
- U.S. states
- 32
- U.S. cities
- 72
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 511.70.01068 Boehringer Ingelheim Investigational Site | Huntsville | Alabama | — | — |
| 511.70.01040 Boehringer Ingelheim Investigational Site | Mobile | Alabama | — | — |
| 511.70.01041 Boehringer Ingelheim Investigational Site | Tucson | Arizona | — | — |
| 511.70.01003 Boehringer Ingelheim Investigational Site | Jonesboro | Arkansas | — | — |
| 511.70.01070 Boehringer Ingelheim Investigational Site | Carmichael | California | — | — |
| 511.70.01026 Boehringer Ingelheim Investigational Site | Redding | California | — | — |
| 511.70.01015 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 511.70.01014 Boehringer Ingelheim Investigational Site | Stanford | California | — | — |
| 511.70.01017 Boehringer Ingelheim Investigational Site | Tarzana | California | — | — |
| 511.70.01072 Boehringer Ingelheim Investigational Site | Torrance | California | — | — |
| 511.70.01078 Boehringer Ingelheim Investigational Site | Vista | California | — | — |
| 511.70.01066 Boehringer Ingelheim Investigational Site | Walnut Creek | California | — | — |
| 511.70.01064 Boehringer Ingelheim Investigational Site | Denver | Colorado | — | — |
| 511.70.01001 Boehringer Ingelheim Investigational Site | Wheat Ridge | Colorado | — | — |
| 511.70.01050 Boehringer Ingelheim Investigational Site | Farmington | Connecticut | — | — |
| 511.70.01006 Boehringer Ingelheim Investigational Site | Hartford | Connecticut | — | — |
| 511.70.01055 Boehringer Ingelheim Investigational Site | New London | Connecticut | — | — |
| 511.70.01024 Boehringer Ingelheim Investigational Site | Aventura | Florida | — | — |
| 511.70.01056 Boehringer Ingelheim Investigational Site | Daytona Beach | Florida | — | — |
| 511.70.01090 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | — | — |
| 511.70.01027 Boehringer Ingelheim Investigational Site | Gainesville | Florida | — | — |
| 511.70.01062 Boehringer Ingelheim Investigational Site | New Port Richey | Florida | — | — |
| 511.70.01043 Boehringer Ingelheim Investigational Site | Orlando | Florida | — | — |
| 511.70.01084 Boehringer Ingelheim Investigational Site | Pembroke Pines | Florida | — | — |
| 511.70.01048 Boehringer Ingelheim Investigational Site | St. Petersburg | Florida | — | — |
| 511.70.01042 Boehringer Ingelheim Investigational Site | Stuart | Florida | — | — |
| 511.70.01063 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 511.70.01085 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 511.70.01086 Boehringer Ingelheim Investigational Site | West Palm Beach | Florida | — | — |
| 511.70.01022 Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| 511.70.01057 Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| 511.70.01087 Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| 511.70.01052 Boehringer Ingelheim Investigational Site | Roswell | Georgia | — | — |
| 511.70.01060 Boehringer Ingelheim Investigational Site | Champaign | Illinois | — | — |
| 511.70.01058 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 511.70.01032 Boehringer Ingelheim Investigational Site | Indianapolis | Indiana | — | — |
| 511.70.01018 Boehringer Ingelheim Investigational Site | Lexington | Kentucky | — | — |
| 511.70.01007 Boehringer Ingelheim Investigational Site | Baton Rouge | Louisiana | — | — |
| 511.70.01047 Boehringer Ingelheim Investigational Site | New Orleans | Louisiana | — | — |
| 511.70.01079 Boehringer Ingelheim Investigational Site | New Orleans | Louisiana | — | — |
| 511.70.01031 Boehringer Ingelheim Investigational Site | Saint Louis | Maryland | — | — |
| 511.70.01011 Boehringer Ingelheim Investigational Site | Haverhill | Massachusetts | — | — |
| 511.70.01028 Boehringer Ingelheim Investigational Site | Detroit | Michigan | — | — |
| 511.70.01081 Boehringer Ingelheim Investigational Site | Detroit | Michigan | — | — |
| 511.70.01082 Boehringer Ingelheim Investigational Site | Billings | Montana | — | — |
| 511.70.01077 Boehringer Ingelheim Investigational Site | Moorestown | New Jersey | — | — |
| 511.70.01019 Boehringer Ingelheim Investigational Site | Endwell | New York | — | — |
| 511.70.01076 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 511.70.01025 Boehringer Ingelheim Investigational Site | Poughkeepsie | New York | — | — |
| 511.70.01067 Boehringer Ingelheim Investigational Site | Purchase | New York | — | — |
| 511.70.01016 Boehringer Ingelheim Investigational Site | Mount Airy | North Carolina | — | — |
| 511.70.01044 Boehringer Ingelheim Investigational Site | Raleigh | North Carolina | — | — |
| 511.70.01049 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 511.70.01089 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 511.70.01054 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 511.70.01075 Boehringer Ingelheim Investigational Site | Dayton | Ohio | — | — |
| 511.70.01002 Boehringer Ingelheim Investigational Site | Mayfield Heights | Ohio | — | — |
| 511.70.01065 Boehringer Ingelheim Investigational Site | Tulsa | Oklahoma | — | — |
| 511.70.01083 Boehringer Ingelheim Investigational Site | Tulsa | Oklahoma | — | — |
| 511.70.01036 Boehringer Ingelheim Investigational Site | Medford | Oregon | — | — |
| 511.70.01004 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 511.70.01021 Boehringer Ingelheim Investigational Site | West Reading | Pennsylvania | — | — |
| 511.70.01073 Boehringer Ingelheim Investigational Site | Warwick | Rhode Island | — | — |
| 511.70.01023 Boehringer Ingelheim Investigational Site | Anderson | South Carolina | — | — |
| 511.70.01035 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 511.70.01008 Boehringer Ingelheim Investigational Site | Nasville | Tennessee | — | — |
| 511.70.01020 Boehringer Ingelheim Investigational Site | Corpus Christi | Texas | — | — |
| 511.70.01009 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 511.70.01030 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 511.70.01091 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 511.70.01013 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 511.70.01005 Boehringer Ingelheim Investigational Site | Salt Lake City | Utah | — | — |
| 511.70.01061 Boehringer Ingelheim Investigational Site | Sandy City | Utah | — | — |
| 511.70.01010 Boehringer Ingelheim Investigational Site | Burlington | Vermont | — | — |
| 511.70.01012 Boehringer Ingelheim Investigational Site | Charlottesville | Virginia | — | — |
| 511.70.01046 Boehringer Ingelheim Investigational Site | Norfolk | Virginia | — | — |
| 511.70.01029 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 511.70.01071 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 511.70.01033 Boehringer Ingelheim Investigational Site | Bellevue | Washington | — | — |
| 511.70.01039 Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
| 511.70.01069 Boehringer Ingelheim Investigational Site | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00360243, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 26, 2016 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00360243 live on ClinicalTrials.gov.